321430-43-7

Basic information

• Product Name: 2-[(2-METHOXYBENZYL)OXY]-1H-ISOINDOLE-1,3(2H)-DIONE
• Synonyms: 2-[(2-METHOXYBENZYL)OXY]-1H-ISOINDOLE-1,3(2H)-DIONE;2-[(2-methoxyphenyl)methoxy]-2,3-dihydro-1H-isoindole-1,3-dione
• CAS NO: 321430-43-7
• Molecular Formula: C₁₆H₁₃NO₄
• Molecular Weight: 283.28
• Mol File: 321430-43-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[(2-METHOXYBENZYL)OXY]-1H-ISOINDOLE-1,3(2H)-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(2-METHOXYBENZYL)OXY]-1H-ISOINDOLE-1,3(2H)-DIONE(321430-43-7)
• EPA Substance Registry System: 2-[(2-METHOXYBENZYL)OXY]-1H-ISOINDOLE-1,3(2H)-DIONE(321430-43-7)

Safety Data

• Hazardous Substances Data: 321430-43-7(Hazardous Substances Data)

Upstream product

• 524-38-9 N-hydroxyphthalimide 
• 612-16-8 (2-methoxyphenyl)methanol 
• 7035-02-1 o-Methoxybenzyl chloride 
• 52289-93-7 o-Methoxybenzyl bromide 

Downstream Products

• 161146-52-7 O-[(2-methoxyphenyl)methyl]hydroxylamine 
• 1446946-04-8 C₁₉H₂₇N₃O₅ 
• 1446946-17-3 C₁₈H₂₇N₃O₄ 
• 1446946-30-0 7-[3-amino-4-(2'-methoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446945-91-0 C₁₉H₂₅N₃O₄ 

Relevant articles and documents

Multifunctional small molecules as potential anti-alzheimer’s disease agents

Alzheimer’s disease (AD) is a severe multifactorial neurodegenerative disorder characterized by a progressive loss of neurons in the brain. Despite research efforts, the pathogenesis and mechanism of AD progression are not yet completely understood. There are only a few symptomatic drugs approved for the treatment of AD. The multifactorial character of AD suggests that it is important to develop molecules able to target the numerous pathological mechanisms associated with the disease. Thus, in the context of the worldwide recognized interest of multifunctional ligand therapy, we report herein the synthesis, characterization, physicochemical and biological evaluation of a set of five (1a–e) new ferulic acid-based hybrid compounds, namely feroyl-benzyloxyamidic derivatives enclosing different substituent groups, as potential anti-Alzheimer’s disease agents. These hybrids can keep both the radical scavenging activity and metal chelation capacity of the naturally occurring ferulic acid scaffold, presenting also good/mild capacity for inhibition of self-Aβ aggregation and fairly good inhibition of Cu-induced Aβ aggregation. The predicted pharmacokinetic properties point towards good absorption, comparable to known oral drugs.

Design, synthesis, molecular docking and biological evaluation of novel coumarin-oxime ether derivatives as COX-2 inhibitors

Coumarin-oxime ether derivatives (14-25) were synthesized by an efficient and straight forward procedure from the reaction of 3-acetyl coumarin (1) and o-substituted benzyl hydroxyl amines (2-13) in pyridinium p-toluenesulfonate/dichloromethane (PPTS/DCM)

NOVEL VASCULAR LEAKAGEAGE INHIBITOR

The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.